Ireland-based Covidien has received 510(k) approval from the US Food and Drug Administration (FDA) for its Sonicision Cordless Ultrasonic Dissection Device with three additional lengths, 13cm, 26cm and 48cm.
Earlier, the system secured approval for the 39cm length.
The system can be used in a wide variety of general, bariatric, colorectal, gynecological and urological surgical procedures.
The approval for new lengths helps surgeons to use the system in additional procedures, including pediatric colectomy, splenectomy, and appendectomy.
Covidien advanced surgical president Chris Barry said the Sonicision system’s groundbreaking cordless technology continues to transform how minimally invasive surgery is performed.
‘These new device lengths enable surgeons to use Sonicision technology in a more diverse range of surgical procedures while avoiding the need for cords and separate generators," Barry added.
The system’s increased mobility reduces the frustration of managing cords in a sterile field and helps to increase procedural efficiencies, said Covidien.
The full cordless ultrasonic portfolio is available in the US, according to the company.
Covidien, which reported revenue of around $10.2bn in 2013, operates in about 150 countries.
Image: The US Food and Drug Administration cleared three new device shaft lengths in addition to the current 39cm device. Photo: courtesy of Business Wire.